Alendronate-associated Osteonecrosis of the Jaws: a Review of the Main Topics

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2013 Aug 30

PMID 23986020

Citations 7

Authors

F Paiva-Fonseca

A-R Santos-Silva

R Della-Coletta

P-A Vargas

M-A Lopes

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates is a group of inorganic pyrophosphates analogues that suppress bone resorption by inducing osteoclast inactivation, being frequently used for management of diseases affecting bone metabolism, bone metastases and bone tumors. However, since 2003 many cases describing the presence of necrotic bone exposures in the jaws have been described in patients receiving these drugs, what represent a signiﬁcant complication of bisphosphonates treatment. The overall incidence of bisphosphonate-related osteonecrosis of the jaws is low, ranging from 0.7% to 12%, mainly observed in those patients receiving intravenously treatment. Osteonecrosis of the jaws associated to oral bisphosphonate, particularly alendronate, has also been reported by a number of authors. Considering that alendronate is one of the most used drug worldwide, specially for treatment of osteoporosis, a better understanding of osteonecrosis of the jaws related to its use and how to manage these patients is extremely important. Therefore, in the current manuscript the authors aim to review the most important topics related to this pathological presentation.

Citing Articles

Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.

Hadad H, Matheus H, Pai S, Souza F, Guastaldi F Arch Oral Biol. 2023; 159():105875.

PMID: 38160519 PMC: 11729500. DOI: 10.1016/j.archoralbio.2023.105875.

Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in osteosarcoma treatment.

Yoo S, Mun Y, Kang N, Koo J, Lee D, Yoo J Bioeng Transl Med. 2023; 8(6):e10472.

PMID: 38023714 PMC: 10658614. DOI: 10.1002/btm2.10472.

Dual Delivery of Alendronate and E7-BMP-2 Peptide via Calcium Chelation to Mineralized Nanofiber Fragments for Alveolar Bone Regeneration.

Boda S, Wang H, John J, Reinhardt R, Xie J ACS Biomater Sci Eng. 2021; 6(4):2368-2375.

PMID: 33455340 PMC: 7818347. DOI: 10.1021/acsbiomaterials.0c00145.

Poly(Aspartic Acid) Functionalized Poly(ϵ-Caprolactone) Microspheres with Enhanced Hydroxyapatite Affinity as Bone Targeting Antibiotic Carriers.

Rotman S, Moriarty T, Nottelet B, Grijpma D, Eglin D, Guillaume O Pharmaceutics. 2020; 12(9).

PMID: 32957602 PMC: 7559286. DOI: 10.3390/pharmaceutics12090885.

Severe bilateral Legg-Calvé-Perthes resolved with pamidronate in combination with casts, physiotherapy and adductor tenotomy: a pictorial essay over 11 years.

Logan L, Haider S, Brauer C, Miettunen P BMJ Case Rep. 2019; 12(9).

PMID: 31537587 PMC: 6754667. DOI: 10.1136/bcr-2019-229919.

References

Diniz-Freitas M, Lopez-Cedrun J, Fernandez-Sanroman J, Garcia-Garcia A, Fernandez-Feijoo J, Diz-Dios P . Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. Med Oral Patol Oral Cir Bucal. 2012; 17(5):e751-8. PMC: 3482517. DOI: 10.4317/medoral.18041. View

Gueiros L, Lopes M, Leao J . Paget's disease and bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2008; 66(6):1319. DOI: 10.1016/j.joms.2008.02.011. View

Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29(8):1548-58. DOI: 10.1016/j.clinthera.2007.08.008. View

Malmgren B, Astrom E, Soderhall S . No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008; 37(4):196-200. DOI: 10.1111/j.1600-0714.2007.00607.x. View

Madrid C, Sanz M . What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009; 20 Suppl 4:87-95. DOI: 10.1111/j.1600-0501.2009.01772.x. View

Migliorati C, Mattos K, Palazzolo M . How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Assoc. 2010; 141(5):562-6. DOI: 10.14219/jada.archive.2010.0229. View

Russell R . Bisphosphonates: the first 40 years. Bone. 2011; 49(1):2-19. DOI: 10.1016/j.bone.2011.04.022. View

Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Gomez-Garcia F . Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract. 2010; 16(5):878-82. DOI: 10.1111/j.1365-2753.2009.01203.x. View

Fugazzotto P, Lightfoot W, Jaffin R, Kumar A . Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol. 2007; 78(9):1664-9. DOI: 10.1902/jop.2007.060514. View

10.

Bauer J, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S . Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg. 2011; 40(3):277-82. DOI: 10.1016/j.jcms.2011.04.011. View

11.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

12.

Sedghizadeh P, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler C . Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009; 140(1):61-6. DOI: 10.14219/jada.archive.2009.0019. View

13.

Kim J, Park Y, Li Z, Shim J, Moon H, Jung H . Effect of alendronate on healing of extraction sockets and healing around implants. Oral Dis. 2011; 17(7):705-11. DOI: 10.1111/j.1601-0825.2011.01829.x. View

14.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

15.

Malden N, Lopes V . An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2011; 30(2):171-82. DOI: 10.1007/s00774-011-0299-z. View

16.

Kos M, Kuebler J, Luczak K, Engelke W . Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg. 2009; 38(4):255-9. DOI: 10.1016/j.jcms.2009.06.005. View

17.

Lo J, ORyan F, Yang J, Hararah M, Gonzalez J, Gordon N . Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011; 59(5):916-22. DOI: 10.1111/j.1532-5415.2011.03371.x. View

18.

Bedogni A, Bettini G, Totola A, Saia G, Nocini P . Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg. 2010; 68(7):1662-6. DOI: 10.1016/j.joms.2010.02.037. View

19.

Conte-Neto N, Bastos A, Spolidorio L, Marcantonio R, Marcantonio Jr E . Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head Face Med. 2011; 7:7. PMC: 3111349. DOI: 10.1186/1746-160X-7-7. View

20.

Shin E, Kwon Y, Herr Y, Shin S, Chung J . Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw. J Periodontal Implant Sci. 2010; 40(2):90-5. PMC: 2872811. DOI: 10.5051/jpis.2010.40.2.90. View